These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15199299)

  • 1. Harnessing the parathyroids to create stronger bones.
    Silver J; Bushinsky D
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):471-6. PubMed ID: 15199299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis.
    Fraser WD; Ahmad AM; Vora JP
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):437-44. PubMed ID: 15199294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the parathyroid glands on bone metabolism.
    Malluche HH; Koszewski N; Monier-Faugere MC; Williams JP; Mawad H
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():23-33. PubMed ID: 16884395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone: a double-edged sword for bone metabolism.
    Qin L; Raggatt LJ; Partridge NC
    Trends Endocrinol Metab; 2004 Mar; 15(2):60-5. PubMed ID: 15036251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
    Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
    Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.
    Tay D; Cremers S; Bilezikian JP
    Br J Clin Pharmacol; 2018 Feb; 84(2):252-267. PubMed ID: 29049872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cellular and clinical parameters of anabolic therapy for osteoporosis.
    Rosen CJ
    Crit Rev Eukaryot Gene Expr; 2003; 13(1):25-38. PubMed ID: 12839095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological regulation of parathyroid hormone secretion.
    Nemeth EF
    Curr Pharm Des; 2002; 8(23):2077-87. PubMed ID: 12171519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone - a bone anabolic and catabolic agent.
    Poole KE; Reeve J
    Curr Opin Pharmacol; 2005 Dec; 5(6):612-7. PubMed ID: 16181808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
    Esbrit P; Alcaraz MJ
    Biochem Pharmacol; 2013 May; 85(10):1417-23. PubMed ID: 23500550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors.
    Gensure RC; Gardella TJ; Jüppner H
    Biochem Biophys Res Commun; 2005 Mar; 328(3):666-78. PubMed ID: 15694400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of ligand recognition by parathyroid hormone 1 (PTH1) and PTH2 receptors.
    Hoare SR; Usdin TB
    Curr Pharm Des; 2001 May; 7(8):689-713. PubMed ID: 11375776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules.
    Goltzman D
    J Bone Miner Res; 1999 Feb; 14(2):173-7. PubMed ID: 9933469
    [No Abstract]   [Full Text] [Related]  

  • 15. Physiology of Parathyroid Hormone.
    Goltzman D
    Endocrinol Metab Clin North Am; 2018 Dec; 47(4):743-758. PubMed ID: 30390810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency.
    Ahmad AM; Hopkins MT; Fraser WD; Ooi CG; Durham BH; Vora JP
    Bone; 2003 Feb; 32(2):170-9. PubMed ID: 12633789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
    Parfitt AM
    Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the role of teriparatide.
    Resmini G; Iolascon G
    Aging Clin Exp Res; 2011 Apr; 23(2 Suppl):30-2. PubMed ID: 21970914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
    Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
    Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.
    John MR; Widler L; Gamse R; Buhl T; Seuwen K; Breitenstein W; Bruin GJ; Belleli R; Klickstein LB; Kneissel M
    Bone; 2011 Aug; 49(2):233-41. PubMed ID: 21514409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.